NCT02709954

Brief Summary

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
7mo left

Started Mar 2016

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Mar 2016Dec 2026

Study Start

First participant enrolled

March 1, 2016

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

March 10, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 16, 2016

Completed
10.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

10.8 years

First QC Date

March 10, 2016

Last Update Submit

April 23, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Road Tracking Error

    baseline, +20, +50, +120, +180 mins after start of alcohol administration

Secondary Outcomes (6)

  • Biphasic Alcohol Effects Scale (BAES)

    baseline, +20, +50, +120, +180, +240 mins after start of alcohol administration

  • Visual Analog Scale (VAS)

    baseline, +20, +50, +120, +180, +240 mins after start of alcohol administration

  • Willingness to Drive Scale

    baseline, +20, +50, +120, +180, +240 mins after start of alcohol administration

  • Cognitive Test Battery

    +40 mins after start of alcohol administration

  • Number of Joints Scale

    baseline, +20, +50, +120, +180, +240 mins after start of alcohol administration

  • +1 more secondary outcomes

Study Arms (4)

Active THC and Placebo Ethanol

EXPERIMENTAL
Drug: Active inhaled delta-9-THCDrug: Placebo

Active THC and Active Ethanol

EXPERIMENTAL
Drug: Active inhaled delta-9-THCDrug: Active Oral Ethanol

Placebo THC and Active Ethanol

EXPERIMENTAL
Drug: PlaceboDrug: Active Oral Ethanol

Placebo THC and Placebo Ethanol

PLACEBO COMPARATOR
Drug: Placebo

Interventions

Low dose THC (\~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or "joint". Administered over 20 minutes via a vaporizer.

Active THC and Active EthanolActive THC and Placebo Ethanol

Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.

Active THC and Placebo EthanolPlacebo THC and Placebo Ethanol

0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.

Active THC and Active EthanolPlacebo THC and Active Ethanol

Eligibility Criteria

Age21 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Males or females 21 to 55 years of age (extremes included).
  • Occasional current cannabis users.
  • Experience with drinking 2 or more standard drinks of alcohol at least once in lifetime.
  • Able to provide informed consent.

You may not qualify if:

  • Cannabis naïve.
  • Alcohol naïve.
  • Positive pregnancy screen
  • Hearing deficits.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Biological Studies Unit, VA Connecticut Healthcare System

West Haven, Connecticut, 06516, United States

Location

MeSH Terms

Conditions

Marijuana Abuse

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental Disorders

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Psychiatry

Study Record Dates

First Submitted

March 10, 2016

First Posted

March 16, 2016

Study Start

March 1, 2016

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

April 29, 2026

Record last verified: 2026-04

Locations